Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Inclusion Criteria: * Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures. * Histologically proven localized adenocarcinoma of the prostate. * High-risk prostate cancer or intermediate-risk prostate cancer defined by D'Amico classification system, with an estimated risk of \>5% of lymph node metastasis. * Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence. * Age ≥ 18 years and ≤ 80 years. * WHO performance status 0-1. * Adequate condition (ASA ≤ III) for general anesthesia and radical prostatectomy surgery. * Baseline Quality of Life (QoL) questionnaires have been completed. Exclusion criteria * Any pre-operative evidence for T4 disease. * Metastatic prostate cancer according to staging or evidence of lymph node metastasis by imaging, defined as any pelvic lymph node \>9 mm in the short axis or positive lymph nodes detected by imaging techniques with sensitivities similar or better than PSMA-PET or Choline-PET prior to surgery. * PSA ≥ 50 ng/ml. * Any prior neo-adjuvant, local or systemic treatment for prostate cancer (alpha reductase inhibitors for treatment of benign hyperplasia are allowed) * Previous pelvic lymph node dissection. * Any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment. * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.